Fujifilm invests $928 million to expand CDMO's biologics production facility in Denmark

Investment will double the site's drug substance manufacturing capacity and will expand its capabilities to include fill/finish, and enhance its current assembly, labeling and packaging services.

The capital investment will also expand the site's capabilities to include fill/finish, and enhance its current assembly, labeling and packaging services.

Production lines for bulk drug substance will be expanded with the addition of a further six mammalian cell bioreactors, bringing the total to 12 x 20,000-L bioreactors by autumn 2023, making the Denmark facility one of the few major large-scale manufacturing facilities in the bio-CDMO industry.

The development will also include the addition of the site's first fill/finish production line (added by summer 2023), featuring a fully-automated, cutting-edge system capable of producing up to approximately 35 million units per annum to cater to large-scale production.

In spring 2022, a new packaging line equipped with facilities to assemble multiple types of auto-injectors, as well as automatic labeling, will be added to meet a broad range of customer needs.

"Since the acquisition of the Denmark site last year, the facility's strong manufacturing track-record, coupled with Fujifilm Diosynth Biotechnologies' technologies enabling a stable supply of high-quality biopharmaceuticals, has led to new orders not only from existing clients but also new clients, contributing to our rapid business expansion," said Takatoshi Ishikawa, executive vice president, general manager of bio-CDMO division, Fujifilm Corporation.

In August 2019, Fujifilm paid 98 billion yen (890 million USD) to acquire Biogen’s manufacturing subsidiary in Denmark.